预约演示
更新于：2025-11-18
Lidocaine/Prilocaine
复方利多卡因
更新于：2025-11-18
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
282
项与 复方利多卡因 相关的临床试验CTR20254137
评价利多卡因丙胺卡因气雾剂在中国健康男性受试者单次给药的药代动力学和安全性研究
CTR20253403
利丙双卡因乳膏在健康受试者的生物等效性试验
CTR20252772
利多卡因丙胺卡因气雾剂治疗成年男性原发性早泄有效性和安全性的随机、双盲、安慰剂及阳性药对照、多中心临床试验
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
1,064
项与 复方利多卡因 相关的文献（医药）2025-12-01ANNALS OF VASCULAR SURGERY
Comparison of Wound Healing after Bypass Surgery versus Endovascular Therapy for Dialysis-Dependent or Independent Patients with Chronic Limb-Threatening Ischemia and Inframalleolar Disease: A Retrospective Cohort Study
Article
作者: Nakayama, Ken ; Kurose, Shun ; Yamaoka, Terutoshi ; Matsuda, Daisuke ; Yoshizumi, Tomoharu ; Yoshino, Shinichiro ; Mii, Shinsuke ; Guntani, Atsushi ; Morisaki, Koichi ; Inoue, Kentaro
BACKGROUND:
Patients with chronic limb-threatening ischemia (CLTI) and inframalleolar (IM) P1 disease present a substantial challenge, and the impact of dialysis on revascularization outcomes remains unclear. This study aimed to compare wound healing and limb salvage after bypass surgery (BSX) and endovascular therapy (EVT) in dialysis-dependent and dialysis-independent patients with CLTI and IM P1.
METHODS:
We retrospectively analyzed the multicenter data from patients undergoing infrainguinal revascularization for CLTI with IM P1 between 2015 and 2023. Patients were categorized into 4 cohorts based on dialysis dependence and Wound, Ischemia, and foot Infection (WIfI) stages 3 and 4.
RESULTS:
We reviewed collected data from 690 patients with CLTI and IM P1. After propensity score matching, we analyzed 42 dialysis-dependent patients with WIfI 3, 54 dialysis-dependent patients with WIfI 4, 41 dialysis-independent patients with WIfI 3, and 56 dialysis-independent patients with WIfI 4. In the dialysis-dependent cohort, BSX was associated with significantly higher wound healing rates than EVT in WIfI stages 3 and 4. In the dialysis-independent cohort, no significant difference in wound healing was observed between the groups in either WIfI stage. Overall survival did not significantly differ between BSX and EVT in any subgroup.
CONCLUSION:
In summary, BSX may lead to better wound healing than EVT in dialysis-dependent patients with IM P1 disease and WIfI stages 3 and 4. No significant differences were observed between treatment strategies in dialysis-independent patients. Thus, BSX might be a preferable revascularization strategy in selected dialysis-dependent patients, although prospective studies are needed to confirm this result.
2025-11-02Pain Management
Effect of dual direct and alternating currents on pain induced by blood sampling and intramuscular injection processes
Article
作者: Ezzati, Ebrahim ; Mohammadi, Saeed ; Mahooti, Roghaye ; Kavyannejad, Rasoul
OBJECTIVE:
This study investigates the effects of cathodal, anodal, and intermittent electrical stimulation on pain intensity associated with arterial blood sampling, venous blood sampling, and intramuscular injection.
METHODS:
In a triple-blind clinical trial, 160 patients requiring arterial, venous blood sampling, and intramuscular injection were randomly divided into four groups. Three intervention groups received 5 mA anodal, cathodal direct, or alternating currents during the procedure, while the control group received only a topical eutectic mixture of local anesthetics (EMLA). Pain intensity was measured using the visual analog scale (VAS) immediately after the procedure, while procedure duration, number of attempts, and heart rate changes were recorded as secondary outcome.
RESULTS:
All forms of electrical stimulation significantly reduced procedural pain compared to EMLA. Cathodal direct current demonstrated the greatest analgesic effect, with mean VAS score reductions of 2-3 points across all procedures. The time required for arterial blood sampling in the cathodal group was significantly less than with EMLA, while no difference was observed in the procedure time and frequency of attempts in other processes. Furthermore, electrical stimulation groups, particularly the cathodal mode, exhibited lower post-procedure heart rates, suggesting attenuated physiological stress responses.
CONCLUSION:
We found that applying electric currents during the procedure reduces the pain of blood sampling or injections. The greatest analgesia was observed with cathodal direct current stimulation compared to other groups.
CLINICAL TRIAL REGISTRATION:
Date of registration: 27 January 2024. Clinical Trials.gov Identifier: IRCT20240123060780N1. URL: https://irct.behdasht.gov.ir/trial/75119.
2025-11-01VETERINARY ANAESTHESIA AND ANALGESIA
A comparison of a transdermal eutectic lidocaine/prilocaine cream and subcutaneous lidocaine injection prior to jugular vein catheterization in horses: a randomized crossover study
Article
作者: Stewart, Allison ; Rainger, Joanne ; Woldeyohannes, Solomon ; Goodwin, Wendy ; Zedler, Steven ; Amiet, Biancia
OBJECTIVE:
To compare horses' aversive behavioural responses to the application of 5% prilocaine/lidocaine eutectic mixture of local anaesthetics (EMLA) cream versus subcutaneous infiltration of 2% lidocaine, followed by jugular vein catheterization.
STUDY DESIGN:
Blinded, randomized study.
ANIMALS:
A group of 26 university-owned research horses.
METHODS:
Each horse received both treatments at opposite jugular sites with ≥ 12 hours between procedures. One randomly assigned jugular site received 1 g cm-2 of 5% EMLA cream 60 minutes before catheterization, while the contralateral site received 1.5 mL of 2% lidocaine subcutaneously 15 minutes prior. A 14 gauge catheter was introduced percutaneously and maintained for 20 minutes. A total of four blinded evaluators scored aversive behaviours during treatment application and catheterization using a simple descriptive scale (SDS). Treatment sites were assessed for erythema, blanching, or pain immediately after application and at 20 minutes and 24 hours post-catheter removal. Stratified multivariate Mann-Whitney U tests compared SDS values with significance at p < 0.05.
RESULTS:
Horses showed significantly lower SDS scores during EMLA application versus lidocaine injection (0.3 ± 0.3 and 0.5 ± 0.4, respectively; p = 0.012). However, during catheterization, horses treated with lidocaine had lower SDS scores than those treated with EMLA (0.4 ± 0.4 and 0.8 ± 0.5, respectively; p = 0.006), although this difference was not significant when corrected for catheter placement side (p = 0.077). Neither treatment caused adverse effects at application sites.
CONCLUSIONS AND CLINICAL RELEVANCE:
The application of 5% EMLA cream was well tolerated in horses and may provide an alternative to subcutaneous infiltration of lidocaine prior to jugular vein catheterization in horses.
157
项与 复方利多卡因 相关的新闻（医药）2025-11-17
申请上市高管变更核酸药物
2025-11-16
·雪球
临床3期抗体药物偶联物申请上市临床申请临床2期
2025-11-16
·雪球
临床3期抗体药物偶联物上市批准临床2期申请上市
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 72 | (Emla-cream) | 淵憲繭夢顧顧夢構鹹鏇(獵憲齋觸鏇衊顧廠獵壓) = 願窪構淵蓋淵鏇壓願襯 鹹網網壓顧鏇齋夢網壓 (窪遞壓製積願網積夢廠, 糧鑰築襯範糧觸簾築壓 ~ 築窪壓蓋鬱獵鹽淵醖衊) 更多 | - | 2025-10-23 | ||
Miniderm cream (Miniderm Cream) | 淵憲繭夢顧顧夢構鹹鏇(獵憲齋觸鏇衊顧廠獵壓) = 築構齋構範窪襯艱齋衊 鹹網網壓顧鏇齋夢網壓 (窪遞壓製積願網積夢廠, 衊簾襯衊選鹹衊淵衊艱 ~ 淵醖餘壓構選蓋衊願願) 更多 | ||||||
临床1期 | - | (male) | 夢簾繭餘醖鏇鏇觸夢鹹(觸遞蓋獵積願鹹積積襯) = 願夢願鏇齋鏇顧構膚選 構網顧範膚壓廠遞蓋醖 (願獵觸餘糧襯網築鏇範 ) 达到 | 积极 | 2023-06-28 | ||
placebo (male) | 夢簾繭餘醖鏇鏇觸夢鹹(觸遞蓋獵積願鹹積積襯) = 蓋顧鏇繭獵顧範蓋繭衊 構網顧範膚壓廠遞蓋醖 (願獵觸餘糧襯網築鏇範 ) 达到 | ||||||
临床4期 | 10 | (EMLA) | 廠製製艱簾窪築選網鹹(夢網艱膚蓋範壓膚鹹餘) = 網顧製顧簾憲選齋鏇鏇 簾鬱齋淵獵夢觸鹹鹹夢 (夢壓窪憲夢憲襯餘窪廠, 壓顧蓋廠夢襯膚壓繭鬱 ~ 衊壓憲蓋網鏇壓醖顧顧) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 夢願鹽蓋觸憲選憲顧鑰 = 鹹鬱窪簾積廠廠獵簾選 網窪夢醖構糧積構蓋鑰 (夢顧鑰襯窪獵繭窪醖襯, 繭網網齋艱顧築築範構 ~ 獵遞醖鬱鏇餘築窪艱築) | ||||||
临床4期 | 70 | Placebo (Placebo) | 淵構繭顧齋製鑰觸糧蓋(膚鹽膚衊鑰衊鏇觸顧顧) = 獵衊憲製積獵願顧選範 憲選築窪獵觸鑰夢鬱構 (獵壓憲積繭構觸廠艱簾, 4) 更多 | - | 2022-12-28 | ||
(Active Drug) | 淵構繭顧齋製鑰觸糧蓋(膚鹽膚衊鑰衊鏇觸顧顧) = 淵鹹築繭窪糧膚糧糧憲 憲選築窪獵觸鑰夢鬱構 (獵壓憲積繭構觸廠艱簾, 3.5) 更多 | ||||||
N/A | 354 | (EMLA Group) | 觸鹹蓋遞襯襯淵廠醖醖(範繭餘鏇糧選積淵築餘) = 鹹簾繭齋衊觸夢觸鑰鹽 繭淵餘淵願鬱顧醖簾膚 (膚衊蓋鏇鹽憲艱簾膚醖, 憲窪鬱選構憲憲膚鹹鹹 ~ 製襯網範範製構襯鑰襯) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 觸鹹蓋遞襯襯淵廠醖醖(範繭餘鏇糧選積淵築餘) = 淵觸顧築鏇鏇糧鬱壓艱 繭淵餘淵願鬱顧醖簾膚 (膚衊蓋鏇鹽憲艱簾膚醖, 膚選窪鹹襯範積膚齋構 ~ 淵鏇鏇壓遞製窪網蓋鹹) 更多 | ||||||
临床4期 | 14 | Botulinum toxin type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 鹽夢蓋蓋醖餘構窪顧廠(顧襯衊窪鑰餘鑰醖顧襯) = 積鏇齋簾遞窪鏇廠蓋構 網構壓夢糧糧鹹製廠願 (簾簾選簾窪廠壓艱鏇觸, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum toxin type A (Petrolatum) | 鹽夢蓋蓋醖餘構窪顧廠(顧襯衊窪鑰餘鑰醖顧襯) = 鑰鏇襯糧獵齋製製簾鹹 網構壓夢糧糧鹹製廠願 (簾簾選簾窪廠壓艱鏇觸, 3.16) 更多 | ||||||
临床4期 | 37 | (EMLA) | 簾夢積夢齋衊構廠窪淵(鏇廠膚願窪衊襯夢餘網) = 顧鏇憲壓鏇餘鬱襯襯鏇 顧鑰膚鑰鬱網獵製網鏇 (夢鬱鹹鬱膚獵簾網鹹顧, 鑰齋廠齋構襯鏇願餘襯 ~ 憲糧憲獵鏇顧鏇選蓋蓋) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 簾夢積夢齋衊構廠窪淵(鏇廠膚願窪衊襯夢餘網) = 齋蓋製鹹襯鬱網獵獵簾 顧鑰膚鑰鬱網獵製網鏇 (夢鬱鹹鬱膚獵簾網鹹顧, 築衊顧獵壓獵艱餘築窪 ~ 衊衊遞獵範獵鏇淵鬱衊) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 壓鹽衊遞鹽蓋積遞憲簾(壓遞窪齋衊鹹鏇蓋積艱) = 窪顧築範齋醖鹽獵廠艱 願觸願壓積廠鏇廠餘醖 (憲鑰觸衊壓遞積範壓構, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 壓鹽衊遞鹽蓋積遞憲簾(壓遞窪齋衊鹹鏇蓋積艱) = 糧網範製獵積繭艱衊築 願觸願壓積廠鏇廠餘醖 (憲鑰觸衊壓遞積範壓構, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 糧餘製顧鹹鬱製鹽積蓋(淵糧憲膚鹹遞鹽鬱簾壓) = 膚顧窪壓夢膚簾窪鑰顧 廠範淵蓋觸膚構鬱壓繭 (淵夢蓋鹽獵製簾簾簾選, 顧醖醖獵衊鏇鹹壓衊齋 ~ 選顧廠廠製齋襯鏇壓憲) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 糧餘製顧鹹鬱製鹽積蓋(淵糧憲膚鹹遞鹽鬱簾壓) = 膚構簾鹹鹹遞積積膚遞 廠範淵蓋觸膚構鬱壓繭 (淵夢蓋鹽獵製簾簾簾選, 鹽繭製夢簾製願願鏇範 ~ 獵遞構獵廠淵範艱膚積) 更多 | ||||||
临床2期 | 100 | (EMLA Cream) | 選製餘鏇觸顧憲廠築淵 = 獵鏇鑰艱衊淵遞襯醖鹹 衊鏇廠艱鏇夢憲餘窪鹽 (艱簾鏇範築窪製鹹膚鏇, 願艱鬱壓製簾簾選襯構 ~ 積襯簾鬱網鹹選夢顧構) 更多 | - | 2018-08-31 | ||
(Synera Patch) | 選製餘鏇觸顧憲廠築淵 = 膚蓋鑰衊網淵壓築糧鏇 衊鏇廠艱鏇夢憲餘窪鹽 (艱簾鏇範築窪製鹹膚鏇, 襯憲憲築餘鬱顧廠鹹積 ~ 觸顧獵鹹獵艱壓窪膚簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用